Recent studies have centered on the overlap of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GIP stimulators are increasingly employed for addressing type 2 T2DM, their unexpected consequences on motivation circuits, specifically influenced by dopamine systems, are receiving substantial focus. This article provid